Effects of Victoza (Liraglutide) Versus Lyxumia (Lixisenatide) on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

Trial Profile

Effects of Victoza (Liraglutide) Versus Lyxumia (Lixisenatide) on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Liraglutide (Primary) ; Lixisenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 24 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Jan 2018.
    • 24 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Jan 2018.
    • 18 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top